CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S24, 2014 Special supplement with the abstract book of LATINFARMA 2013 Oral Communication CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS Machado-Alba JE, Murillo MM, Machado ME. Grupo Investigación Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Pereira, Colombia. E-mail: machado@utp.edu.co; jormach66@hotmail.com Abstract Objective: To determine the … Continue reading CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS

J Pharm Pharmacogn Res 2(Suppl. 1): S24, 2014

Special supplement with the abstract book of LATINFARMA 2013

Oral Communication

CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS

Machado-Alba JE, Murillo MM, Machado ME.

Grupo Investigación Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Pereira, Colombia. E-mail: machado@utp.edu.co; jormach66@hotmail.com
Abstract

Objective: To determine the effectiveness of lipid-lowering therapy in a sample of patients affiliated with the Colombian Health System.

Methods: The cross-sectional study was conducted between January 1, 2010 and June 30, 2011. Of a total of 8316 patients, a random sample of 600 people from ten cities was stratified according to dyslipidemia. Information on socio-demographic and anthropometric characteristics, risk factors, pharmacological and laboratory variables were obtained from medical records.

Results: There was a female predominance (56.2%) with a mean age of 65.1 ± 11.5 years in the subjects, and 93.2% had hypertension, 29.0% had diabetes mellitus, and 10.2% had a history of myocardial infarction. The patients were treated with lovastatin alone (84.1%), gemfibrozil (12.3%) at doses below those recommended and atorvastatin (1.8%). In patients with a high cardiovascular risk, 38.6% achieved goals for LDL-C levels (<100 mg/dL), while 49.4% of those with a moderate risk reached the target level (<130 mg/dL). On average, there was a 4.9% reduction in LDL-C. Sex, age, personal history of cardiovascular disease and diabetes mellitus, use of hydrochlorothiazide and poor therapy adherence were statistically associated with a lack of control of dyslipidemia.

Conclusions: Because a lack of control over LDL-C levels occurred in men over 55 years, diabetic patients, or those with a history of cardiovascular disease, who received lower doses of lovastatin or were non-adherent to treatment, it is recommended that the dose be increased based on clearly defined therapeutic objectives and that the presence of comorbidities be assessed, which will then be treated properly.

Alendronate and platelet-rich plasma in sheep anterior cruciate ligament
J. Pharm. Pharmacogn. Res., vol. 12, no. 3, pp. 526-538, May-Jun 2024. DOI: https://doi.org/10.56499/jppres23.1845_12.3.526 Original Article Effect of alendronate and platelet-rich plasma in tendon-bones integration in sheep anterior cruciate ligament surgery [Efecto del alendronato y del plasma rico en plaquetas en la integración tendón-hueso en la cirugía del ligamento cruzado anterior ovino] Tangkas Sibarani1*, Bambang … Continue reading Alendronate and platelet-rich plasma in sheep anterior cruciate ligament
Brassicaceae selenium complexes versus SARS-COV-2 MAP4 and spike protein
J. Pharm. Pharmacogn. Res., vol. 12, no. 3, pp. 514-525, May-Jun 2024. DOI: https://doi.org/10.56499/jppres23.1739_12.3.514 Original Article Antiviral potential of selenium complexes from Brassicaceae by inhibiting protein bond between MAP4 and the spike of SARS-CoV-2 [Potencial antiviral de complejos de selenio de Brassicaceae mediante la inhibición de la unión proteica entre MAP4 y la espiga de … Continue reading Brassicaceae selenium complexes versus SARS-COV-2 MAP4 and spike protein
Andrographis paniculata and cardiovascular diseases
J. Pharm. Pharmacogn. Res., vol. 12, no. 3, pp. 487-513, May-Jun 2024. DOI: https://doi.org/10.56499/jppres23.1841_12.3.487 Review Andrographis paniculata: A potential supplementary therapy for cardiovascular diseases - A systematic review of its effects and molecular actions [Andrographis paniculata: Una terapia suplementaria potencial para las enfermedades cardiovasculares - Una revisión sistemática de sus efectos y acciones moleculares] Oluebube … Continue reading Andrographis paniculata and cardiovascular diseases

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio